Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026
Amneal (NASDAQ: AMRX) will report its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before market open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Amneal (NASDAQ: AMRX) will report its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, before market open. The company will host an audio webcast at 8:30 a.m. ET and post results and the live webcast via the Investor Relations website.
Investors can register for the webcast on the company IR site or join by conference line at 1 (833) 470-1428 (U.S.) using access code 937407; international toll-free numbers and a replay will be posted after the call.
Details
News Market Reaction – AMRX
On Jan 27, the day this news came out, AMRX closed 1.92% above the previous close.
Data tracked by StockTitan Argus for the Jan 27 session.
Key Figures
- 2025 net revenue guidance
- $3.0B–$3.1B
- Full-year 2025 guidance from <b>Jan 13, 2026</b> 8-K
- 2025 adjusted EBITDA
- $675M–$685M
- Full-year 2025 guidance from <b>Jan 13, 2026</b> 8-K
- 2025 adjusted diluted EPS
- $0.75–$0.80
- Full-year 2025 guidance from <b>Jan 13, 2026</b> 8-K
- 2025 operating cash flow
- $300M–$330M
- Full-year 2025 guidance from <b>Jan 13, 2026</b> 8-K
- 2025 capital expenditures
- $100M
- Net of $20M alliance contribution, full-year 2025 guidance
- Estimated net leverage
- 3.6x
- As of Dec 31, 2025, versus 3.9x a year earlier
- Q3 2025 net revenue
- $784.5M
- Q3 2025 10-Q, up from $702.5M year over year
- Q3 2025 operating income
- $70.3M
- Q3 2025 10-Q, down from $88.8M year over year
Historical Context
-
Collaboration and option deal for KFRX06 Parkinson’s candidate pre-IND development.
-
FDA approvals of two denosumab biosimilars referencing Prolia and XGEVA.
-
FDA approval of epinephrine injection vials for institutional hospital use.
-
Positive interim Phase 4 CREXONT data improving Good On time and symptoms.
-
Participation in upcoming investor conferences with webcast presentations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this here. The access code for the call is 937407. A replay of the conference call will be posted shortly after the call.
About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 290 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.
Investor Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.